Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Novavax hands top execs $106M in stock options as COVID-19 vaccine nears the starting line
Original Vaccitech investor: Biotech no COVID one-hit wonder, as IPO injects $110M for broad pipeline
Leapfrog safety ratings highlight top performers' COVID-19 prevention measures
Novavax handed an extra $147M from legacy Warp Speed program as spotlight shines brighter
UPDATED Coronavirus tracker: Novant Health brings mobile vaccine units into vulnerable communities
COVID-19 tracker: Pfizer to send Canada U.S.-made vaccine doses; EU members push for Valneva supply deal
Pharma advertising leapfrogged the norm during the pandemic—and creativity is flourishing, exec says
Gilead's $1.5B in remdesivir sales help buoy worse-than-expected declines for mainstay HIV, hepatitis C drugs
CMS extends special enrollment period qualifications in latest ACA rule

Featured Story

Novavax hands top execs $106M in stock options as COVID-19 vaccine nears the starting line

By Kevin Dunleavy

Off its successful development of a COVID-19 vaccine, Novavax awarded its brain trust with more than $106 million in stock options in 2020. Four execs made more than $20 million, including CEO Stanley Erck who collected $48 million.

Original Vaccitech investor: Biotech no COVID one-hit wonder, as IPO injects $110M for broad pipeline

By Annalee Armstrong

As Vaccitech prices a $110.5 million IPO, one investor says the company has a pipeline that could address a number of killer diseases long after the headlines over the AstraZeneca vaccine’s blood clot concerns fade.

Leapfrog safety ratings highlight top performers' COVID-19 prevention measures

By Dave Muoio

The biannual report handed out "A" grades to a third of the 2,735 hospitals up for review. The watchdog group also invited its highest achievers to share the organizational practices they leaned on during the pandemic.

Novavax handed an extra $147M from legacy Warp Speed program as spotlight shines brighter

By Ben Adams

A biotech with a long and often troubled past is hoping 2021 will be its year, and it’s just been handed a major tranche of cash to help make that happen.

UPDATED Coronavirus tracker: Novant Health brings mobile vaccine units into vulnerable communities

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

COVID-19 tracker: Pfizer to send Canada U.S.-made vaccine doses; EU members push for Valneva supply deal

By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner

Pfizer will begin shipping U.S.-made doses of its COVID-19 vaccine to Canada beginning next week, officials say. Meanwhile, the company and its partner BioNTech have asked Europe's drug regulator to expand use of their vaccine to people aged 12 and older. And more headlines.

Pharma advertising leapfrogged the norm during the pandemic—and creativity is flourishing, exec says

By Beth Snyder Bulik

Pharma advertising creativity is flourishing thanks to the pandemic, says Klick Health creative chief Rich Levy. With in-person commercial shoots canceled, traditional media plans upended and a major shift to digital in every part of the business, drugmakers and their ad agencies had to get inventive.

Gilead's $1.5B in remdesivir sales help buoy worse-than-expected declines for mainstay HIV, hepatitis C drugs

By Noah Higgins-Dunn

The COVID-19 pandemic took a worse-than-expected hit against Gilead Sciences' core drug sales during the first quarter, although executives predicted its antiviral remdesivir should continue to play a key role over the next few quarters amid a sluggish global pandemic recovery.

CMS extends special enrollment period qualifications in latest ACA rule

By Robert King

CMS finalized another raft of regulations for the 2022 coverage year on the ACA's insurance exchanges, including a lower out-of-pocket cost maximum for beneficiaries.

COVID-19 Tracker